Eastman Kodak Company: 10-Q Filing Summary
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for Eastman Kodak Company for the period ended June 30, 1995. The company operates primarily in Consumer Imaging and Commercial Imaging segments. During this period, Kodak continued the divestiture of its non-imaging health businesses (pharmaceutical, consumer health, and clinical diagnostics), which are reported as discontinued operations.
Key Financial Metrics
| Metric (in millions) | Q2 1995 | Q2 1994 | YTD 1995 | YTD 1994 |
|---|---|---|---|---|
| Total Revenues | $3,992 | $3,469 | $7,201 | $6,248 |
| Net Earnings | $377 | $264 | $639 | $346 |
| Earnings Per Share (Diluted) | $1.11 | $0.79 | $1.88 | $1.04 |
| Gross Profit Margin | 48.5% | 48.0% | 48.5% | 47.4% |
| Operating Cash Flow (YTD) | $511 | $193 | $511 | $193 |
| Cash & Equivalents (End of Period) | $823 | $491 | $823 | $491 |
| Total Debt (Short + Long Term) | $1,161 | $1,031 | $1,161 | $1,031 |
Note: Debt figures derived from Short-term borrowings ($507M) and Long-term borrowings ($654M) as of June 30, 1995.
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 15% in Q2 and 14% year-to-date compared to 1994. Excluding the acquisition of Qualex (a photofinishing company), organic sales grew 11% for the quarter and 10% year-to-date.
- Profitability: Net earnings rose 43% in Q2 and 85% year-to-date. This improvement was driven by higher volumes, manufacturing productivity, favorable foreign currency effects, and lower interest expense.
- Cash Position: Cash and cash equivalents decreased significantly from $2,020 million at year-end 1994 to $823 million at June 30, 1995. This decline is primarily attributed to approximately $1.3 billion in tax payments related to the divestiture of non-imaging health businesses.
- Segment Performance:
- Consumer Imaging: Sales up 20% (Q2) and 23% (YTD). Operating earnings increased 5% (Q2) and 14% (YTD).
- Commercial Imaging: Sales up 11% (Q2) and 9% (YTD). Operating earnings surged 67% (Q2) and 33% (YTD), aided by volume gains in motion picture and professional imaging.
Outlook, Risks, and Unusual Items
- Divestitures: The company announced an agreement to sell its pharmaceutical R&D facility to SmithKline Beecham for approximately $120 million. Proceeds are expected to align with estimates.
- Dividends: A cash dividend of $0.40 per share ($137 million total) was declared in Q2 1995. Total YTD dividends were $273 million.
- Capital Expenditures: Capital additions for the first half of 1995 were $459 million, down from $627 million in the prior year period.
- Legal and Environmental: Kodak is a participant in the EPA's TSCA Compliance Audit Program with an anticipated liability of $1 million. The company is also a potentially responsible party (PRP) at approximately 25 Superfund sites; however, management expects future costs to be immaterial.
- Compensation Plans: Shareholders approved the 1995 Long-term Compensation Plan and Management Variable Compensation Plan, which utilize Return on Net Assets (RONA) as a primary performance criterion.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of operations given the $1.2 billion drop in cash reserves due to tax payments on divestitures.
- Organic Growth: Confirm the 10-11% organic sales growth figures by excluding the impact of the Qualex acquisition.
- Divestiture Completion: Monitor the closing of the pharmaceutical R&D facility sale and the finalization of other non-imaging health business divestitures.
- Environmental Liabilities: Review updates on Superfund site allocations and the EPA TSCA audit penalties.
- Foreign Currency Impact: Assess the sensitivity of future earnings to foreign exchange rate fluctuations, which contributed $318 million to YTD sales.